BioMed Nexus Daily Updates
Your essential biotech, medtech, and pharma recap — no noise, just what matters.
Monday, September 14, 2026
📌TL;DR
AstraZeneca said Saturday that SERENA-4, the 1,371 patient first line trial of Etcamah (camizestrant) plus palbociclib, missed its primary progression free survival endpoint, eight days after the drug's September 4 US accelerated approval; the approved ctDNA switch indication is unaffected, and no medians or hazard ratios were disclosed.
At WCLC in Seoul, Hansoh's risvutatug rezetecan posted median overall survival of 18.5 versus 10.3 months against topotecan in relapsed small cell lung cancer, a hazard ratio of 0.46, in the 461 patient ARTEMIS-008 interim analysis; GSK holds rights outside Greater China.
Zipalertinib plus chemotherapy hit median progression free survival of 14.5 versus 8.5 months in first line EGFR exon 20 insertion lung cancer in REZILIENT3, hazard ratio 0.50; Amgen's DeLLphi-305 numbers had still not been presented as of Sunday night.
SK Biopharmaceuticals said it has not paid the Biohaven upfront and will close the Kv7 license only after the FDA hold resolves, which it expects between October and November, per the Seoul Economic Daily; RISE 3's 2026 topline stands.
The FDA extended its zanzalintinib review from December 3 to March 3 as a major amendment, per Reuters and Endpoints; Exelixis closed down 2.3 percent Friday.
Lilly's $50 million purchase of Sangamo's platforms closed September 4, per an 8-K, and Axogen priced its BioCircuit funding offering at $42.50 for about $208.7 million gross.
⚡ Executive Takeaway
The week we spent documenting the market's discount on surrogate promises ended with the cleanest specimen imaginable, delivered into a quiet Saturday: the same molecule the FDA approved on a ctDNA switching strategy failed the conventional trial that would have made it a franchise. Nothing about that sequence is contradictory. SERENA-6 asked a narrow question and answered it; SERENA-4 asked the broad one and the drug came up short. But the industry has spent a decade treating approval as the moment a program de risks, and this weekend severed that equation in public. The label held. The franchise did not. What is left is a drug whose entire first line story is the biomarker gate the market was busy discounting last week.
The transferable lesson is that a clever endpoint gets you a label the size of the endpoint, no larger, and the market now prices the difference immediately. That sets this week's job. Five withheld or forced numbers come due on dates nobody can move: the DeLLphi-305 figures inside the WCLC window, Amgen's OCEAN(a) language Tuesday, the Amylyx close disclosure by roughly Thursday, the UX111 decision Friday, Grail's briefing documents around Sunday. We will grade each one as it lands. Forced disclosure week begins now.
🎗️ Breast Cancer
AstraZeneca kept the label and lost the bigger question. AZN
SERENA-4 randomized 1,371 untreated advanced ER positive, HER2 negative breast cancer patients to camizestrant plus palbociclib or anastrozole plus palbociclib, and the camizestrant arm's progression free survival advantage did not reach statistical significance. AstraZeneca disclosed the miss by press release on Saturday, September 12, withholding medians and hazard ratios, with oncology chief Susan Galbraith saying the result "sharpens our focus" on the approved population. That population is the SERENA-6 one: patients whose ctDNA shows an ESR1 mutation emerging on first line therapy, approved September 4. The class pattern is now three first line oral SERD misses in a row, and the broad franchise bet moves to the roughly 10,000 patient CAMBRIA adjuvant program. AZN closed Friday at $160.17, before the disclosure; Monday's open is the reaction.
🫁 Lung Cancer
Seoul put hard numbers on the board while the biggest dataset stayed silent. GSK | CGEM | AMGN | AZN
Two WCLC Presidential Symposium readouts printed real figures. Hansoh's B7-H3 antibody drug conjugate risvutatug rezetecan, GSK partnered outside Greater China, cut the risk of death 54 percent versus topotecan in relapsed small cell lung cancer, median overall survival 18.5 versus 10.3 months in the 461 patient, China conducted ARTEMIS-008 interim; a second B7-H3 ADC, in TAISHAN-302, was positive against the same comparator per congress coverage. Cullinan and Taiho's zipalertinib added six months of median progression free survival in first line exon 20 disease, 14.5 versus 8.5 months in REZILIENT3. Trastuzumab deruxtecan's DESTINY-Lung04 met its first line HER2 mutant endpoint per congress coverage. The dataset everyone actually came for, Amgen and AstraZeneca's DeLLphi-305, had shown no numbers as of Sunday night, with the meeting running through Tuesday.
🧠 Neuro
SK put a date on the Biohaven hold and a condition on the cash. BHVN
Speaking at a September 11 briefing reported by the Seoul Economic Daily, SK Biopharmaceuticals strategy head Yoo Chang-ho said Biohaven will submit the requested metabolite data to the FDA between late September and early October, expects the partial hold resolved between October and November, and confirmed the two companies "have signed, but the upfront payment has not yet been made. We will resolve the clinical hold and then close the transaction." That makes the $350 million due at closing under the announced terms explicitly contingent on an FDA nonclinical review. RISE 3, fully enrolled, keeps its 2026 topline per both companies; RISE 2 recruitment stays paused. BHVN closed Friday at $12.71, roughly flat on the day.
🏛️ Regulatory
Exelixis just showed what answering an FDA question costs in December. EXEL
The FDA moved its decision on zanzalintinib plus atezolizumab in metastatic colorectal cancer from December 3, 2026 to March 3, 2027, after Exelixis submitted updated safety and efficacy data in response to an agency information request and the submission was classified a major amendment, per Reuters, Endpoints News, and Benzinga; no specific new concern was identified in the reporting. EXEL closed at $56.12, down 2.3 percent. The pattern now includes Capricor's November 22 date, extension risk flagged on Summit's November 14 decision, and queue reviews at Scholar Rock and Ultragenyx. A three month slip is becoming the standing price of a late cycle information request, which is worth applying to every fourth quarter action date you are carrying.
💰 The Resolved Ledger
Two of our longest running open items closed on primary documents. LLY | AXGN
The Lilly purchase of Sangamo's platform assets closed September 4, per an 8-K Sangamo filed September 8: $50 million in cash for the STAC-BBB capsid platform, zinc finger technology, the Modular Integrase editing platform, the ST-506 prion program, and associated milestone and royalty rights. We had carried this at "report only after a primary confirms" since the expected close date passed; the filing is that primary. PTC's companion purchase from the $163.55 million auction remains unconfirmed. Separately, Axogen priced 4,910,000 shares at $42.50, about $208.7 million gross, funding the BioCircuit cash purchase; AXGN closed Friday at $42.16, a half percent below the offer price, which is as clean a placement as a deal funding raise gets in this tape.
🧬 People
The R&D chair shuffle got dates and a second name. TAK | NVO
Takeda's Andy Plump departure now has a date: June 2027, per both Fierce Biotech and Endpoints News, which settles the timing we withheld Thursday when only one outlet carried it. Novo Nordisk named a new global research head the same day, per Endpoints, continuing the reorganization under research chief Martin Holst Lange. And the FDA's new oncology chief Angelo De Claro used his first interview, with Fierce, to put staff hiring and AI deployment at the top of the oncology office's list. Three data points, one pattern: the people who will run late decade R&D and its regulation are being chosen now, in a compressed window.
📋 Quick Hits
Amylyx logged a tenth consecutive close below its $35.50 offer price at $31.62 Friday; the offering close remained unannounced as of Sunday night, with the greenshoe window forcing disclosure by roughly September 18 and a Morgan Stanley appearance Tuesday.
Disc Medicine presented initial Phase 2 RESTORE-PV results at the SOHO annual meeting, setting up a polycythemia vera challenge in which BioSpace still ranks Silence Therapeutics' divesiran ahead on timeline.
A Tokyo court rejected an IHH Healthcare unit's multibillion yen damages claim against Daiichi Sankyo over the Fortis dispute, per Pharma Japan and other coverage.
BioSpace added detail to the Samsung Biologics contract we carried Thursday: the $262 million agreement runs through 2033 with a European pharma company; the client is still unnamed in verifiable reporting.
The FDA cleared an AI algorithm that flags harder to detect heart attacks on EKGs, per STAT; Fierce's oral GLP-1 tracker has Novo's Wegovy pill and Lilly's Foundayo both growing scripts; Alzheon is planning a major raise despite its Phase 3 Alzheimer's miss, per Endpoints.
Still absent as of Sunday night: an Overton hearing date, a tenth MFN signatory, ADARx and Oura pricings, an Etcamah launch price, and any DeLLphi-305 figure.
📖 In Today's Full Analysis
Be sure to read the full article for all the details, including:
The SERENA-4 versus SERENA-6 table: two definitions of first line, and why one approval survived the other's failure
The full WCLC readout table with every ARTEMIS-008 and REZILIENT3 figure, sourced to the company releases
The Biohaven timeline: what SK says happens between late September and November, and what the $350 million now waits on
The major amendment ledger and the week ahead calendar, from Tuesday's Morgan Stanley test through the Friday UX111 decision
📋 The Week in Review
Tuesday: Amgen fell 10.1 percent on olpasiran readacross, three sponsors issued numberless late stage toplines in one day, and the FDA approved Etcamah on the SERENA-6 ctDNA signal while making Davis and Mikhail permanent at CDER and CBER.
Wednesday: Bayer's Hyrnuo won first line accelerated approval on a 75 percent response rate, and Solstice, Encoded, and Caspian raised a combined $550 million in a day.
Thursday: the FDA paused Biohaven's opakalim enrollment fifteen days after the SK deal, Artisan Partners demanded Novartis board changes, Axogen agreed to buy BioCircuit for $200 million, and Frazier closed $1.1 billion.
Friday through Sunday: the surrogate discount week closed with NVS down 14.1 percent and nothing round tripped; then SERENA-4 missed on Saturday and WCLC opened in Seoul with the ARTEMIS-008 and REZILIENT3 numbers.
🔒 BioMed Nexus Pro
In Today's Pro Brief...
🧠 The SERENA split: why Saturday's miss vindicates the discount, the arithmetic on what Etcamah's first line story is now worth, and the one disclosure AstraZeneca still owes before anyone can model it
💊 The B7-H3 order of battle after Seoul: the specific discount we apply to an 18.5 month China number, and what a rival's published survival curve does to the price of Amgen's silence this week
📊 The $350 million that became an FDA decision: the three scenario map for SK's close gate, the leverage inversion nobody is pricing if RISE 3 reads out first, and the filing clause to watch
🎯 Plus the full catalyst calendar, rebuilt for forced disclosure week: five dated events by Sunday, the new March 3 zanzalintinib date, and the tenth Amylyx close
Last week the market priced what withheld numbers might hide. This week five of them come due on dates nobody can move, and we will grade each one as it lands. What are you watching? Reply to this email.
Sponsorship slots for 2026 are limited. See packages and pricing →
NEW: BioMed Nexus Signals, weekly sales intelligence for life sciences BD teams. Learn more →